Compare Moderna, Inc. (MRNA) vs D Wave Quantum Inc (QBTS) Price & Performance

Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.

Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.

D-Wave Quantum (QBTS) trades at $14.42, down 5.26% today, amid bearish technical signals and ongoing legal investigations. The company shows severe financial stress with a -2,001.59% net income margin and -$355M net loss in 2025, though it maintains a 64.19% gross margin. Revenue declined from $25M to $12M year-over-year, while cash flow turned negative in 2026. Despite 100% analyst buy ratings with a $34.38 consensus target, multiple law firms are investigating potential securities law violations.

The stock faces significant fundamental challenges with massive losses and declining revenue, offset by strong analyst optimism about quantum computing potential. Key risks include ongoing legal probes, cash burn acceleration, and competitive pressures in the emerging quantum sector. The current price sits 58% below analyst targets, creating potential upside if execution improves, but substantial operational turnaround is needed.